No photo of Sadia Zafar
  • PL 21 (Haartmaninkatu 3)



If you made any changes in Pure these will be visible here soon.

Personal profile


  • 3122 Cancers

International and National Collaboration Publications and projects within past five years.

Publications 2017 2019

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs

Heiniö, C., Sorsa, S., Siurala, M., Grönberg-Vähä-Koskela, S., Havunen, R., Haavisto, E., Koski, A., Hemminki, O., Zafar, S., Cervera-Carrascon, V., Munaro, E., Kanerva, A. & Hemminki, A., 1 Jun 2019, In : Human Gene Therapy. 30, 6, p. 740-752 13 p.

Research output: Contribution to journalArticleScientificpeer-review

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy

Santos, J. M., Cervera-Carrascon, V., Havunen, R., Zafar, S., Siurala, M., Sorsa, S., Anttila, M., Kanerva, A. & Hemminki, A., 5 Sep 2018, In : Molecular therapy. 26, 9, p. 2243-2254 12 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

Zafar, S., Sorsa, S., Siurala, M., Hemminki, O., Havunen, R., Cervera-Carrascon, V., Santos, J. M., Wang, H., Lieber, A., De Gruijl, T., Kanerva, A. & Hemminki, A., 2018, In : OncoImmunology. 7, 10, 10 p., 1490856.

Research output: Contribution to journalArticleScientificpeer-review

CD40L coding oncolytic adenovirus 3 is a potent facilitator of dendritic cell therapy.

Zafar, S., Siurala, M. O., Sorsa, S., Hemminki, O. J., Havunen, R. S. A., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A-M. & Hemminki, A. E., 2017.

Research output: Conference materialsPosterResearch